NASDAQ:ME - Nasdaq - US90138Q3065 - Common Stock - Currency: USD
2.42
-0.32 (-11.68%)
The current stock price of ME is 2.42 USD. In the past month the price decreased by -31.25%. In the past year, price decreased by -78.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.97 | 82.08B | ||
CVS | CVS HEALTH CORP | 11.71 | 79.88B | ||
LH | LABCORP HOLDINGS INC | 17.15 | 20.84B | ||
DGX | QUEST DIAGNOSTICS INC | 19.1 | 19.12B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.55B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
DVA | DAVITA INC | 14.99 | 11.68B | ||
HIMS | HIMS & HERS HEALTH INC | 112 | 10.77B | ||
CHE | CHEMED CORP | 23.84 | 8.18B | ||
CRVL | CORVEL CORP | 25.97 | 5.57B | ||
OPCH | OPTION CARE HEALTH INC | 26.89 | 5.45B | ||
GH | GUARDANT HEALTH INC | N/A | 5.30B |
23andMe Holding Co. is a US-based company operating in Health Care Providers & Services industry. The company is headquartered in South San Francisco, California and currently employs 560 full-time employees. The company went IPO on 2020-10-06. 23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
23ANDME HOLDING CO -CLASS A
349 Oyster Point Boulevard
South San Francisco CALIFORNIA US
CEO: Josh Bayliss
Employees: 571
Company Website: https://investors.23andme.com/
Investor Relations: https://investors.23andme.com/
Phone: 16509386300
The current stock price of ME is 2.42 USD. The price decreased by -11.68% in the last trading session.
The exchange symbol of 23ANDME HOLDING CO -CLASS A is ME and it is listed on the Nasdaq exchange.
ME stock is listed on the Nasdaq exchange.
10 analysts have analysed ME and the average price target is 2.12 USD. This implies a price decrease of -12.33% is expected in the next year compared to the current price of 2.42. Check the 23ANDME HOLDING CO -CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
23ANDME HOLDING CO -CLASS A (ME) has a market capitalization of 64.93M USD. This makes ME a Micro Cap stock.
23ANDME HOLDING CO -CLASS A (ME) currently has 571 employees.
23ANDME HOLDING CO -CLASS A (ME) has a resistance level at 3.02. Check the full technical report for a detailed analysis of ME support and resistance levels.
The Revenue of 23ANDME HOLDING CO -CLASS A (ME) is expected to grow by 22.44% in the next year. Check the estimates tab for more information on the ME EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ME does not pay a dividend.
23ANDME HOLDING CO -CLASS A (ME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.2).
The outstanding short interest for 23ANDME HOLDING CO -CLASS A (ME) is 6.9% of its float. Check the ownership tab for more information on the ME short interest.
ChartMill assigns a fundamental rating of 3 / 10 to ME. The financial health of ME is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ME reported a non-GAAP Earnings per Share(EPS) of -13.2. The EPS decreased by -29.41% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -192.93% | ||
ROE | -603.67% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 42% to ME. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -329.17% and a revenue growth 22.44% for ME